Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | SLC10A1 | Q14973 | 5/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19346901 | 0.90 | SLC10A1 (0.35) | PGRSLC10A1 | |
| SCHEMBL21889977 | 0.82 | SLC10A1 (0.47) | SLC10A1 | |
| SCHEMBL30035645 | 0.80 | SLC10A1 (0.45) | MAPTNPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL19332126 | 0.80 | SLC10A1 (0.45) | MAPTNPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL21889633 | 0.77 | — | — | |
| SCHEMBL22510932 | 0.76 | SLC10A1 (0.33) | PGRSLC10A1 | |
| SCHEMBL21890572 | 0.74 | SLC10A1 (0.42) | SLC10A1 | |
| SCHEMBL22511208 | 0.74 | GRM4 (0.36) | TSHRPGRSLC10A1 | |
| SCHEMBL26542958 | 0.73 | SLC10A1 (0.36) | NPC1RAB9ASLC10A1 | |
| SCHEMBL19332070 | 0.73 | SLC10A1 (0.41) | MAPTSMN1; SMN2TSHRSLC10A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017156255-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |